Organigram Holdings Still a Buy?

OrganigramOrganigram Holdings Inc. (NASDAQ: OGI) is a Canadian medical and recreational cannabis company that is priced right in the sweet spot for bargain investors. The company serves all of the Canadian market and has access to legal overseas markets thanks to its home nation’s liberal cannabis laws.

Organigram had an impressive 2019 fiscal year, with revenue growing by 546.98%. This explosive growth was hindered by the Coronavirus Pandemic in 2020 with an interruption to both production and retail operations. This resulted in revenue growth of just 7.94% last year. As Canada’s economy reopens and restrictions are removed, analysts are optimistic that the company will get back on the growth path.

There’s speculation in this pick but it’s based on the company’s strong history. There are products in the pipeline, including pre-rolled marijuana, that could give Organigram a stronger competitive edge. In the most recent quarter, the company’s recovery was already underway with net revenue growth of 30% and positive cash flow from operations for the first time in months.

The stock’s affordability and the company’s long-term viability as a cannabis grower and retailer make it a bargain stock worth considering in March.

Key Data:

  • 1 Year Price Growth: 37%
  • YTD Price Growth: 08%
  • 3 Month Price Growth: 57%

All information is based on current and historical market data, as well as publicly available financial data. As with any financial decision, your own research is important. Stock market outcomes can never be 100% accurately predicted. Familiarity with historical data, individual industries, and individual stocks is key to developing a robust portfolio. Note that stock prices can fluctuate rapidly during trading sessions.


The reports, research and newsletter are based on current and historical market data, as well as publicly available financial data.They are intended to be a starting point for investors. They do not provide every material fact about a company or industry, nor are they recommendations to buy or sell. The writers and the company make no warranties or representations as to the accuracy of these reports.   You should NOT rely solely upon the information or opinions read in the content. Rather, you should use the content as a starting point for doing independent research on the independent analysis and trading methods in the content. The content is impersonal and does not provide individualized advice or recommendations for any specific reader or individual portfolio. By accessing this website you have agreed to our disclaimers and privacy policy.


You May Also Like

About the Author: Writocity